SUBSCRIBE
SUBSCRIBE
News   Drug Development

GlaxoSmithKline’s Pazopanib Shows Promise in Ovarian Cancer

September 15, 2008 | 
1 min read
LONDON, Sept 15 (Reuters) - GlaxoSmithKline's experimental drug pazopanib appears to be effective in fighting ovarian cancer, based on measurements of a biological marker used to predict tumour recurrence, researchers said on Monday.
Clinical research Phase 2 Europe
GSK
MORE ON THIS TOPIC
Business people and concepts vector art exit
Business
Takeda’s long-term R&D head announces exit after major pipeline reorganization
September 10, 2026
 · 
2 min read
 · 
Gabrielle Masson
Alarm clock with pause sign, take a break, menopause concept, hormone replacement therapy
FDA
Biohaven takes another hit as FDA pauses enrollment in pivotal trials for embattled epilepsy drug
September 10, 2026
 · 
3 min read
 · 
Heather McKenzie
Vector cartoon illustration of a business team standing at a crossroad with multiple arrows, discussing and choosing the right path toward success and future opportunities.
Drug pricing
Drugmakers cherry pick launch regions as MFN creates ‘policy environment like an earthquake’
September 10, 2026
 · 
4 min read
 · 
Annalee Armstrong
Composite collage picture image of man slide down arrow recession statistics data weird freak bizarre unusual fantasy billboard comics.
Bladder cancer
Tyra shares slip as bladder cancer responses fall short of investor expectations
September 10, 2026
 · 
2 min read
 · 
Tristan Manalac